Dachaigh › Ailseachadh nan Sgamhan › Illinois › Chicago
Sgrùdaidhean clionaigeach Ailseachadh nan Sgamhan ann an Chicago, IL
Tha 41 sgrùdaidhean airson Ailseachadh nan Sgamhan a’ lorg phàirtichean aig làraichean ann agus timcheall air Chicago (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- agus 1 a bharrachd
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- agus 1 a bharrachd
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
A’ fastadhÌre 1/2
- University of Illinois Hospital & Health Sciences System ( Site 0044), Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 2
- University of Illinois Cancer Center, Chicago
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
A’ fastadhÌre 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
A’ fastadhÌre 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
A’ fastadhÌre 3
- Northwestern University, Chicago
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A’ fastadhÌre 3
- University of Illinois Cancer Center, Chicago
- Center for Care and Discovery, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
A’ fastadhÌre 3
- University of Illinois Chicago, Chicago
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- Rush University Medical Center, Chicago
- University of Illinois Chicago, Chicago
A Registry for People With Lung Cancer
A’ fastadhSgrùdadh amharc
- Rush University Medical Center (Data collection only), Chicago
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
A’ fastadhÌre 2
- Research Site, Chicago
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A’ fastadhÌre 2/3
- Rush University Medical Center, Chicago
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
A’ fastadhÌre 1/2
- University of Chicago Comprehensive Cancer Center, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
A’ fastadhÌre 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A’ fastadhÌre 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A’ fastadhÌre 3
- University of Illinois Hospital and Health Sciences Systems, Chicago
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
A’ fastadhÌre 3
- Northwestern University, Chicago
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
A’ fastadhÌre 1
- Xencor Investigative Site, Chicago
- Xencor Investigative Site, Chicago
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
A’ fastadhÌre 2
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
A’ fastadh
- Northwestern University, Chicago
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
A’ fastadhÌre 1/2
- University of Chicago, Chicago
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A’ fastadhÌre 1/2
- Northwestern Memorial Hospital, Chicago
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
A’ fastadhÌre 2/3
- Northwestern University, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A’ fastadhÌre 1/2
- Northwestern Memorial Hospital, Chicago
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
A’ fastadhÌre 2
- University of Illinois Cancer Center, Chicago
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
A’ fastadhFàilte do shaor-thoilich fhallain
- University of Illinois at Chicago, Chicago
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
A’ fastadhÌre 2
- University of Chicago Medicine, Chicago
Lung Cancer Screening in High-risk Black Individuals
A’ fastadhFàilte do shaor-thoilich fhallain
- University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
A’ fastadhÌre 1
- The University of Chicago Comprehensive Cancer Center, Chicago
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
A’ fastadhSgrùdadh amharc
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Chicago
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
A’ fastadhSgrùdadh amharc
- University of Chicago, Chicago
Olaparib in Patients With HRD Malignant Mesothelioma
A’ fastadhÌre 2
- University of Chicago Medical Center, Chicago
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
A’ fastadhSgrùdadh amharc
- Thoracic Surgery, Canning Thoracic Institute (Northwestern Memorial Hospital), Chicago
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
A’ fastadhSgrùdadh amharc
- Northwestern University, Chicago
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
A’ fastadhÌre 2
- Northwestern University, Chicago
Sgrùdaidhean Ailseachadh nan Sgamhan ann am bailtean eile
- Houston, TX78 sgrùdaidhean
- Boston, MA62 sgrùdaidhean
- New York City, NY60 sgrùdaidhean
- Los Angeles, CA45 sgrùdaidhean
- Washington, DC41 sgrùdaidhean
- Arlington, VA41 sgrùdaidhean
- Nashville, TN40 sgrùdaidhean
- Baltimore, MD40 sgrùdaidhean
- St. Louis, MO39 sgrùdaidhean
- Columbus, OH37 sgrùdaidhean
- Philadelphia, PA36 sgrùdaidhean
- Seattle, WA33 sgrùdaidhean
Sgrùdaidhean eile ann an Chicago
- Aillse Sgamhain Neo-chealla-beag61 sgrùdaidhean
- Aillse a' bhroilleach58 sgrùdaidhean
- Aillse (gach seòrsa)51 sgrùdaidhean
- Ailse metastatach45 sgrùdaidhean
- Aillse Prostata45 sgrùdaidhean
- Obesity41 sgrùdaidhean
- Cancer Ovarian36 sgrùdaidhean
- Buailteach34 sgrùdaidhean
- Aillse colorectal33 sgrùdaidhean
- Fàilligeadh a' Chridhe31 sgrùdaidhean
- Ro-throm28 sgrùdaidhean
- Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil26 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.